Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis

This paper investigates potential cardiovascular and other effects of long-term pharmacological interleukin 1 (IL-1) inhibition.

The results suggest that long-term dual IL-1α/β inhibition could increase cardiovascular risk and, conversely, reduce the risk of development of rheumatoid arthritis. The cardiovascular risk might, in part, be mediated through an increase in proatherogenic lipid concentrations.

Stay in the know

Our latest health headlines delivered to your inbox.